RxDoctor Payments Data

Samir Al-Kabbani, MD

Neurology · Knoxville, TNNPI 1083681183

Payments from drug & device makers

$20,018in general payments, 2019–2025

Across 1,147 payments — averaging $17.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$2K
  • Neurelis, Inc.$2K
  • AbbVie$1K
  • Novartis$1K
  • Biogen$1K
  • Sunovion Pharmaceuticals Inc.$1K
  • plus $11K from 41 others

What the payments were for

  • Food & beverage$19,925100%
  • Education$930%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,018 in reported general payments places this provider in the 70th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$50,932
Medicare patients
124
Services billed
3,415

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)85$373,515
AptiomEslicarbazepine Acetate175$351,273
Kesimpta PenOfatumumab22$201,256
FycompaPerampanel112$146,614
BriviactBrivaracetam94$140,303
NuedextaDextromethorphan Hbr/Quinidine82$134,304
KeppraLevetiracetam42$119,425
Avonex Pen (4 Pack)Interferon Beta-1a12$115,038
TysabriNatalizumab13$108,255
VimpatLacosamide83$104,839
Keppra XrLevetiracetam50$88,888
BotoxOnabotulinumtoxina39$82,352
Oxtellar XrOxcarbazepine28$59,399
Lamictal XrLamotrigine13$55,315
BanzelRufinamide12$53,603

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sunovion Pharmaceuticals Inc.Aptiom$1,134$351,273175 claims
UCB, Inc.Briviact, Vimpat$2,179$245,142177 claims
Eisai Inc.Fycompa, Banzel$1,032$200,217124 claims
Avanir Pharmaceuticals, Inc.Nuedexta$949$134,30482 claims
BiogenTysabri$1,167$108,25513 claims
AbbVieBotox, Ubrelvy, Namzaric$1,217$107,80764 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$695$59,39928 claims
SK Life Science, Inc.Xcopri$722$26,69524 claims
PfizerNurtec Odt$54$21,16914 claims
Neurelis, Inc.Valtoco$1,845$7,53611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 361 neurology providers in Tennessee.

Other neurology in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →